BANK VONTOBEL/CALL/BRISTOL-MYERS SQUIBB/58/0.1/20.09.24 | Market Closed - Deutsche Boerse AG 01:41:55 2024-07-16 pm EDT | ||
| 0.005 EUR | 0.00% |
|
| Current month | +25.00% | ||
| 1 month | -28.57% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 0.005 | 0.00% |
| 24-07-15 | 0.005 | +25.00% |
| 24-07-12 | 0.004 | 0.00% |
| 24-07-11 | 0.004 | 0.00% |
| 24-07-10 | 0.004 | +33.33% |
Delayed Quote Deutsche Boerse AG
Last update July 16, 2024 at 01:41 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Vontobel
|
| WKN | VM7NZ5 |
| ISIN | DE000VM7NZ52 |
| Date issued | 2023-12-29 |
| Strike | 58 $ |
| Maturity | 2024-09-20 (66 Days) |
| Parity | 10 : 1 |
| Emission price | 0.17 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.26 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.015 € |
| Spread % | 75.00% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
40.15
USD
Average target price
52.69
USD
Spread / Average Target
+31.24%
- Stock Market
- Warrants
- Warrant
